BCTX (BriaCell Therapeutics Corp.) stock: $3.95, $34.5M market cap, $20.5M cash, $14.0M EV, $64.2M fully diluted market cap. Next expected readout: Dec-27. Lead program: SV-BR-1-GM (Breast Cancer), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
BriaCell Therapeutics is a clinical-stage biotechnology company developing targeted immunotherapies for cancer, with lead programs Bria-OTS and Bria-Pros+SVF in Phase 3 and Phase 2 studies for breast and prostate cancers.
Breast Cancer; Metastatic Breast Cancer; Breast Neoplasm
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 3 · ActiveModality: allogeneic whole cell-based cancer vaccine
Indications
Metastatic breast cancer(Phase 3)
Catalysts
— 1H 2026
Status note Pivotal Phase 3 (NCT06072612) of Bria-IMT + retifanlimab (anti-PD-1, manufactured by Incyte) in advanced metastatic breast cancer; FDA Fast Track; enrollment on track per Dec 2025 update (230+ screened, 160+ enrolled).
Status note Phase 1/2 study ongoing (NCT06471673).
Bria-OTS+
Stage not disclosed · ActiveModality: personalized off-the-shelf immunotherapy
Aliases Bria-BRES+
Indications
Advanced metastatic breast cancer(Stage not disclosed)
Status note Open IND for clinical evaluation in advanced metastatic breast cancer; first of the enhanced Bria-OTS+ immunotherapies. No trial start stated.
Bria-PROS+
Stage not disclosed · ActiveModality: personalized off-the-shelf immunotherapy
Indications
Prostate cancer(Stage not disclosed)
Status note Cell line manufacturing complete for prostate cancer; no clinical study stated in filing.
Per-asset detail extracted from the 10-Q filed 2026-06-09. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Breast Cancer; Metastatic Breast Cancer; Breast Neoplasm
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.